ResMed Inc. (NYSE:RMD) Shares Acquired by Oregon Public Employees Retirement Fund

Oregon Public Employees Retirement Fund grew its stake in shares of ResMed Inc. (NYSE:RMD) by 98.9% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 64,372 shares of the medical equipment provider’s stock after purchasing an additional 32,007 shares during the period. Oregon Public Employees Retirement Fund’s holdings in ResMed were worth $9,976,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently made changes to their positions in the company. Voya Investment Management LLC increased its position in ResMed by 0.6% in the 3rd quarter. Voya Investment Management LLC now owns 80,431 shares of the medical equipment provider’s stock worth $10,867,000 after purchasing an additional 452 shares during the last quarter. Voloridge Investment Management LLC boosted its stake in shares of ResMed by 748.7% during the 3rd quarter. Voloridge Investment Management LLC now owns 64,316 shares of the medical equipment provider’s stock worth $8,690,000 after acquiring an additional 56,738 shares in the last quarter. Public Employees Retirement System of Ohio boosted its stake in shares of ResMed by 3.5% during the 3rd quarter. Public Employees Retirement System of Ohio now owns 57,728 shares of the medical equipment provider’s stock worth $7,800,000 after acquiring an additional 1,971 shares in the last quarter. California State Teachers Retirement System boosted its stake in shares of ResMed by 1.1% during the 3rd quarter. California State Teachers Retirement System now owns 260,475 shares of the medical equipment provider’s stock worth $35,193,000 after acquiring an additional 2,948 shares in the last quarter. Finally, Man Group plc boosted its stake in shares of ResMed by 149.8% during the 3rd quarter. Man Group plc now owns 92,624 shares of the medical equipment provider’s stock worth $12,515,000 after acquiring an additional 55,543 shares in the last quarter. 66.60% of the stock is owned by institutional investors and hedge funds.

In other news, insider David Pendarvis sold 4,739 shares of the stock in a transaction that occurred on Monday, February 3rd. The stock was sold at an average price of $162.37, for a total value of $769,471.43. Following the completion of the transaction, the insider now directly owns 135,303 shares of the company’s stock, valued at approximately $21,969,148.11. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, insider James Hollingshead sold 1,200 shares of the stock in a transaction that occurred on Thursday, January 2nd. The stock was sold at an average price of $155.40, for a total value of $186,480.00. Following the completion of the transaction, the insider now directly owns 93,174 shares of the company’s stock, valued at $14,479,239.60. The disclosure for this sale can be found here. Insiders sold a total of 50,024 shares of company stock valued at $7,569,645 in the last quarter. Corporate insiders own 1.22% of the company’s stock.

Shares of RMD stock opened at $174.51 on Tuesday. The stock has a 50 day moving average of $160.34 and a two-hundred day moving average of $144.27. The company has a current ratio of 2.60, a quick ratio of 1.85 and a debt-to-equity ratio of 0.61. ResMed Inc. has a 12 month low of $96.63 and a 12 month high of $173.29. The company has a market capitalization of $24.80 billion, a P/E ratio of 55.64, a P/E/G ratio of 3.34 and a beta of 0.48.

ResMed (NYSE:RMD) last announced its quarterly earnings data on Thursday, January 30th. The medical equipment provider reported $1.21 EPS for the quarter, topping the Zacks’ consensus estimate of $1.01 by $0.20. ResMed had a return on equity of 27.25% and a net margin of 16.34%. The company had revenue of $736.20 million during the quarter, compared to the consensus estimate of $723.08 million. During the same quarter last year, the company earned $1.00 EPS. The company’s quarterly revenue was up 13.1% on a year-over-year basis. Sell-side analysts predict that ResMed Inc. will post 4.29 earnings per share for the current fiscal year.

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, March 19th. Shareholders of record on Thursday, February 13th will be given a $0.39 dividend. The ex-dividend date is Wednesday, February 12th. This represents a $1.56 dividend on an annualized basis and a dividend yield of 0.89%. ResMed’s dividend payout ratio is currently 42.86%.

Several research firms have recently issued reports on RMD. Needham & Company LLC reiterated a “hold” rating on shares of ResMed in a research note on Friday, October 25th. CLSA began coverage on ResMed in a research note on Monday, February 3rd. They set an “underperform” rating for the company. Oppenheimer began coverage on ResMed in a research note on Thursday, January 9th. They set a “hold” rating for the company. KeyCorp initiated coverage on ResMed in a research note on Friday, November 22nd. They set a “sector weight” rating for the company. Finally, UBS Group downgraded ResMed from a “buy” rating to a “neutral” rating and set a $174.00 target price for the company. in a research note on Friday, January 31st. One analyst has rated the stock with a sell rating, six have assigned a hold rating and three have given a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and a consensus target price of $133.33.

ResMed Company Profile

ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications that diagnose, treat, and manage respiratory disorders comprising sleep disordered breathing, chronic obstructive pulmonary disease, neuromuscular disease, and other chronic diseases. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, portable oxygen concentrators, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes.

Further Reading: How much money do you need to begin day trading?

Want to see what other hedge funds are holding RMD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ResMed Inc. (NYSE:RMD).

Institutional Ownership by Quarter for ResMed (NYSE:RMD)

Receive News & Ratings for ResMed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ResMed and related companies with MarketBeat.com's FREE daily email newsletter.